279 related articles for article (PubMed ID: 18223215)
61. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
[TBL] [Abstract][Full Text] [Related]
62. Essential role of Notch4/STAT3 signaling in epithelial-mesenchymal transition of tamoxifen-resistant human breast cancer.
Bui QT; Im JH; Jeong SB; Kim YM; Lim SC; Kim B; Kang KW
Cancer Lett; 2017 Apr; 390():115-125. PubMed ID: 28108315
[TBL] [Abstract][Full Text] [Related]
63. MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells.
Kim S; Jeon M; Lee JE; Nam SJ
Oncol Rep; 2016 Apr; 35(4):2398-404. PubMed ID: 26780941
[TBL] [Abstract][Full Text] [Related]
64. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
65. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.
Ijichi N; Shigekawa T; Ikeda K; Horie-Inoue K; Shimizu C; Saji S; Aogi K; Tsuda H; Osaki A; Saeki T; Inoue S
Horm Cancer; 2012 Aug; 3(4):147-59. PubMed ID: 22476979
[TBL] [Abstract][Full Text] [Related]
66. BST-2 is a potential activator of invasion and migration in tamoxifen-resistant breast cancer cells.
Yi EH; Yoo H; Noh KH; Han S; Lee H; Lee JK; Won C; Kim BH; Kim MH; Cho CH; Ye SK
Biochem Biophys Res Commun; 2013 Jun; 435(4):685-90. PubMed ID: 23702480
[TBL] [Abstract][Full Text] [Related]
67. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.
Ghayad SE; Vendrell JA; Bieche I; Spyratos F; Dumontet C; Treilleux I; Lidereau R; Cohen PA
J Mol Endocrinol; 2009 Feb; 42(2):87-103. PubMed ID: 18984771
[TBL] [Abstract][Full Text] [Related]
68. PI3-kinase/p38 kinase-dependent E2F1 activation is critical for Pin1 induction in tamoxifen-resistant breast cancer cells.
Lee KY; Lee JW; Nam HJ; Shim JH; Song Y; Kang KW
Mol Cells; 2011 Jul; 32(1):107-11. PubMed ID: 21573702
[TBL] [Abstract][Full Text] [Related]
69. Elevation of cysteine consumption in tamoxifen-resistant MCF-7 cells.
Ryu CS; Kwak HC; Lee JY; Oh SJ; Phuong NT; Kang KW; Kim SK
Biochem Pharmacol; 2013 Jan; 85(2):197-206. PubMed ID: 23123664
[TBL] [Abstract][Full Text] [Related]
70. Dependency of Tamoxifen Sensitive and Resistant ER
Bhasin S; Dusek C; Peacock JW; Cherkasov A; Wang Y; Gleave M; Ong CJ
Cells; 2023 Jun; 12(13):. PubMed ID: 37443749
[TBL] [Abstract][Full Text] [Related]
71. Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation.
Chiang WF; Cheng TM; Chang CC; Pan SH; Changou CA; Chang TH; Lee KH; Wu SY; Chen YF; Chuang KH; Shieh DB; Chen YL; Tu CC; Tsui WL; Wu MH
Oncogene; 2018 Jan; 37(1):116-127. PubMed ID: 28892050
[TBL] [Abstract][Full Text] [Related]
72. Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro.
Scott DJ; Parkes AT; Ponchel F; Cummings M; Poola I; Speirs V
Int J Oncol; 2007 Sep; 31(3):557-65. PubMed ID: 17671682
[TBL] [Abstract][Full Text] [Related]
73. Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer.
Fiorillo M; Sotgia F; Sisci D; Cappello AR; Lisanti MP
Oncotarget; 2017 Mar; 8(12):20309-20327. PubMed ID: 28411284
[TBL] [Abstract][Full Text] [Related]
74. Altered radiation responses of breast cancer cells resistant to hormonal therapy.
Luzhna L; Lykkesfeldt AE; Kovalchuk O
Oncotarget; 2015 Jan; 6(3):1678-94. PubMed ID: 25682200
[TBL] [Abstract][Full Text] [Related]
75. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers.
Blumenthal RD; Leon E; Hansen HJ; Goldenberg DM
BMC Cancer; 2007 Jan; 7():2. PubMed ID: 17201906
[TBL] [Abstract][Full Text] [Related]
76. Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically.
Morgan L; Gee J; Pumford S; Farrow L; Finlay P; Robertson J; Ellis I; Kawakatsu H; Nicholson R; Hiscox S
Cancer Biol Ther; 2009 Aug; 8(16):1550-8. PubMed ID: 19830888
[TBL] [Abstract][Full Text] [Related]
77. Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer.
Duxbury MS; Matros E; Ito H; Zinner MJ; Ashley SW; Whang EE
Ann Surg; 2004 Oct; 240(4):667-74; discussion 675-6. PubMed ID: 15383794
[TBL] [Abstract][Full Text] [Related]
78. CXCL10 mediates breast cancer tamoxifen resistance and promotes estrogen-dependent and independent proliferation.
Wu X; Sun A; Yu W; Hong C; Liu Z
Mol Cell Endocrinol; 2020 Jul; 512():110866. PubMed ID: 32417506
[TBL] [Abstract][Full Text] [Related]
79. Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer.
Tiwary R; Yu W; deGraffenried LA; Sanders BG; Kline K
Breast Cancer Res; 2011; 13(6):R120. PubMed ID: 22115051
[TBL] [Abstract][Full Text] [Related]
80. Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.
Xiong R; Patel HK; Gutgesell LM; Zhao J; Delgado-Rivera L; Pham TND; Zhao H; Carlson K; Martin T; Katzenellenbogen JA; Moore TW; Tonetti DA; Thatcher GRJ
J Med Chem; 2016 Jan; 59(1):219-237. PubMed ID: 26681208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
